Results 51 to 60 of about 17,710 (254)
Conjunctivitis in patients with atopic dermatitis treated with dupilumab
Drugs in Context, 2020 Atopic dermatitis (AD) is a common, chronic, inflammatory skin disorder with high physical and emotional burden. Robust evidence suggests that interleukin (IL)-4 and IL- 13 are key cytokines in the immunopathogenesis of AD.
Sandra Ferreira, Tiago Torres
doaj +1 more source
Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid
Frontiers in Immunology, 2021 BackgroundBullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed.
Yihua Zhang +7 more
doaj +1 more source
Dupilumab for bullous pemphigoid with intractable pruritus [PDF]
, 2019 Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. Treatment regimens typically include topical and systemic immunosuppressive medications.
Eichenfield, Dawn Z +2 more
core
Clinical Pharmacology &Therapeutics, EarlyView.Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley +1 more source
World Allergy Organization JournalDupilumab is effective for chronic spontaneous urticaria (CSU), but its clinical benefit of switching to dupilumab in omalizumab-resistant CSU remains unclear.This prospective pilot study evaluated the effectiveness of dupilumab in 12 CSU patients whose ...
Koremasa Hayama, M.D., Ph.D. +2 more
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617)
Jenny‐Hoa Nguyen +8 more
wiley +1 more source
Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
Brazilian Journal of OtorhinolaryngologyObjective: Eosinophilic Otitis Media (EOM) is an intractable disease caused by type 2 inflammation, such as Eosinophilic Chronic Rhinosinusitis (ECRS) and bronchial asthma. Biologics have recently been used to treat ECRS and bronchial asthma.
Seiichiro Kamimura +6 more
doaj +1 more source
Keratoconjunctivitis associated with atopic dermatitis treated with tocilizumab [PDF]
, 2018 La dermatitis atópica es una enfermedad cutánea inflamatoria crónica, de diagnóstico esencialmente clínico que se manifiesta en forma de prurito y brotes recurrentes de eccema de localización típica 1 .
Ferrando Piqueres, Raúl +3 more
core +4 more sources
Journal of Cutaneous Immunology and Allergy, 2022 Dupilumab demonstrated high efficacy and tolerable safety profiles in moderate‐to‐severe atopic dermatitis (AD) patients in clinical trials; however, certain patients suffer from facial redness, while obtaining good responses on the trunk and limbs to ...
Hideaki Uchida +10 more
doaj +1 more source
Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation [PDF]
, 2016 Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe ...
Lim, Jonathan Chee Woei +3 more
core +1 more source